StocktoriaOnconetix, Inc. ONCO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $815,371 | $2.5M | $58,465 | — | — |
| Gross profit | $632,913 | $1.1M | -$1.1M | — | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M |
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Free cash flow | — | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M |
| Shareholders' equity | $15.8M | $8.5M | $1.4M | $22.4M | $1.4M |
| Ratios | |||||
| Gross margin | 77.6% | 41.8% | -1927.9% | — | — |
| Operating margin | -2190.0% | -2238.0% | -61634.5% | — | — |
| Net margin | -1721.0% | -2325.2% | -63986.5% | — | — |
| FCF margin | — | -416.9% | -23235.0% | — | — |
| Return on assets | -56.3% | -208.3% | -42.7% | -51.0% | -110.8% |
| Return on equity | -89.0% | -687.0% | -2663.6% | -59.9% | -236.2% |
| Current ratio | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 |
| Revenue growth | -67.7% | 4217.3% | — | — | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001782107 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.